Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6118855 | 0.87 | KDM4E (0.55) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL29562450 | 0.84 | KDM4E (0.49) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL1119372 | 0.84 | KDM4E (0.49) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL2821342 | 0.83 | ALDH1A1 (0.47) | KDM4EGAAALDH1A1HSD17B10HPGD | |
| SCHEMBL25213358 | 0.82 | KDM4E (0.51) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL20903073 | 0.81 | XDH (0.49) | KDM4EPOLBXDHGAAALDH1A1 | |
| SCHEMBL30486068 | 0.81 | XDH (0.49) | KDM4EPOLBXDHGAAALDH1A1 | |
| SCHEMBL5094601 | 0.81 | KDM4E (0.63) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL505337 | 0.81 | KDM4E (0.50) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL8188265 | 0.81 | KDM4E (0.46) | KDM4EPOLBGAAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4602031-A1 | METHODS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025106644-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ALPHA-V BETA-1 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024081904-A1 | METHODS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081904-A1 | METHODS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| EP-1218358-B1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1218358-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-6399603-B1 | QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY | ASTRAZENECA AB (SE) | 2002-06-04 | — | — | US | disclosed |
| EP-0938471-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001021598-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| EP-0938471-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5929097-A | INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1998016503-A2 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | KDM4E 2420/4885POLB 2406/4885XDH 370/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | KDM4E 1806/4885POLB 1510/4885XDH 699/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | KDM4E 1720/4885POLB 1558/4885XDH 684/4885 |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | PIK3R1, PIK3R5, PIK3R2 | KDM4E 3903/4885POLB 1233/4885XDH 2871/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | KDM4E 3061/4885POLB 2484/4885XDH 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.